Sumitomo Pharma Co., Ltd. has resolved to issue up to 59 million new shares, planning to raise approximately 116.4 billion yen. The funds raised will be allocated to research and development in the oncology field and to strengthen the financial base.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4005","jir_company_name":"Sumitomo Chemical Company, Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4005-20260408-01.pdf","jir_short_summary":"Sumitomo Pharma Co., Ltd. has resolved to issue up to 59 million new shares, planning to raise approximately 116.4 billion yen. The funds raised will be allocated to research and development in the oncology field and to strengthen the financial base.","jir_summary":"### Overview of Capital Policy\nAt the Board of Directors meeting on April 8, 2026, Sumitomo Pharma Co., Ltd. resolved to issue up to 59 million new shares (public offering and third-party allotment) and to conduct a share offering. The estimated total net proceeds upper limit is approximately 116.4 billion yen, and this will be implemented as a global offering targeting institutional investors both domestically and internationally. The issue price is scheduled to be determined between April 20 and 23, 2026.\n\n### Use of Proceeds and Impact on Shareholders\nThe funds raised will be applied as follows: 3 billion yen for promoting clinical trials in the oncology field, 1 billion yen for research and development in neurodegenerative diseases and infectious diseases, 1 billion yen to strengthen regenerative and cell therapy businesses, 1 billion yen for enhancing production and quality systems and IT system investments, and the remaining amount for repayment of interest-bearing debt. Although Sumitomo Chemical\u2019s voting rights ratio will decrease, its status as a consolidated subsidiary will be maintained. Additionally, this capital increase includes plans for the initial optional redemption of hybrid bonds.","jir_financial_highlights":"Number of Shares Issued (Public Offering): 51,304,400 shares (Unknown)\nNumber of Shares Issued (Third-Party Allocation): 7,695,600 shares (Unknown)\nFunds Raised (Estimated Net Proceeds Upper Limit): 116,490,277,000 yen (Unknown)\nTotal Number of Outstanding Shares (After Public Offering): 449,204,554 shares (Unknown)\nTotal Number of Outstanding Shares (After Third-Party Allocation): 456,900,154 shares (Unknown)","jir_category":"","jir_hashtags":"#SumitomoChemical, #CapitalPolicy, #NewShareIssuance","jir_key_figures":"Public Offering Shares: 51,304,400 shares\nThird-Party Allocation Shares: 7,695,600 shares\nMaximum Funds Raised: 116,490,277,000 yen","jir_meta_title":"Sumitomo Pharma to Raise Approximately 116.4 Billion Yen through Up to 59 Million New Shares Issuance","jir_meta_description":"Sumitomo Pharma, a subsidiary of Sumitomo Chemical, has resolved to issue up to 59 million new shares. The approximately 116.4 billion yen raised will be allocated to oncology research and development and strengthening the financial base.","jir_og_title":"Sumitomo Pharma Announces Fundraising of Approximately 116.4 Billion Yen through New Share Issuance","jir_og_description":"Sumitomo Pharma Co., Ltd. has resolved to issue up to 59 million new shares. The funds will support enhanced R&D and financial stability.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7702,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-39520","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n